Structural insights into binding specificity, efficacy and bias of a beta2AR partial agonist.Masureel, M., Zou, Y., Picard, L.P., van der Westhuizen, E., Mahoney, J.P., Rodrigues, J.P.G.L.M., Mildorf, T.J., Dror, R.O., Shaw, D.E., Bouvier, M., Pardon, E., Steyaert, J., Sunahara, R.K., Weis, W.I., Zhang, C., Kobilka, B.K.
(2018) Nat. Chem. Biol. 14: 1059-1066
- PubMed: 30327561
- DOI: 10.1038/s41589-018-0145-x
- Primary Citation of Related Structures:
- PubMed Abstract:
Salmeterol is a partial agonist for the β <sub>2 </sub> adrenergic receptor (β <sub>2 </sub>AR) and the first long-acting β <sub>2 </sub>AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Sa ...
Salmeterol is a partial agonist for the β 2 adrenergic receptor (β 2 AR) and the first long-acting β 2 AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol's safety and mechanism of action have both been controversial. To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound β 2 AR in complex with an active-state-stabilizing nanobody. The structure reveals the location of the salmeterol exosite, where sequence differences between β 1 AR and β 2 AR explain the high receptor-subtype selectivity. A structural comparison with the β 2 AR bound to the full agonist epinephrine reveals differences in the hydrogen-bond network involving residues Ser204 5.43 and Asn293 6.55 . Mutagenesis and biophysical studies suggested that these interactions lead to a distinct active-state conformation that is responsible for the partial efficacy of G-protein activation and the limited β-arrestin recruitment for salmeterol.
D. E. Shaw Research, New York, NY, USA.,Geneus Technologies, Ltd, Chengdu, Sichuan, People's Republic of China.,Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. email@example.com.,Dropbox, New York, NY, USA.,Structural Biology Research Center, VIB, Brussels, Belgium.,Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.,Monash Institute for Pharmaceutical Sciences, Monash University, Victoria, Australia.,Department of Computer Science, Stanford University, Stanford, CA, USA.,Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.,Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA.,Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. firstname.lastname@example.org.,Department of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montreal, Montreal, Québec, Canada.,Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, USA.,Department of Structural Biology, Stanford University, Stanford, CA, USA.,Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Computer Science and Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.